We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI icon
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM icon
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GOSS icon
51
Gossamer Bio
GOSS
$54.7M
$3.92M 0.28%
5,854
+1,170
+25% +$725K
2021 Q3
3 quarters
ANAB icon
52
AnaptysBio
ANAB
$1.42B
$3.71M 0.26%
182,717
+68,552
+60% +$1.52M
2021 Q3
3 quarters
ARKK icon
53
PUT
ARK Innovation ETF
ARKK
$8.55B
$3.59M 0.26%
+90,000
New +$4.28M
2022 Q2
0 quarters
IONS icon
54
Ionis Pharmaceuticals
IONS
$7.19B
$3.2M 0.23%
86,311
-72,495
-46% -$2.73M
2021 Q2
4 quarters
AFMD icon
55
DELISTED
Affimed
AFMD
$3.13M 0.22%
+113,076
New +$3.87M
2022 Q2
0 quarters
A icon
56
Agilent Technologies
A
$48.7B
$2.41M 0.17%
20,264
+1,009
+5% +$124K
2020 Q4
6 quarters
ISRG icon
57
Intuitive Surgical
ISRG
$151B
$1.72M 0.12%
8,591
+428
+5% +$100K
2021 Q1
5 quarters
CLDX icon
58
PUT
Celldex Therapeutics
CLDX
$2.2B
$1.63M 0.12%
+60,600
New +$1.76M
2022 Q2
0 quarters
RVTY icon
59
Revvity
RVTY
$17.1B
$1.46M 0.1%
10,293
+505
+5% +$75.7K
2021 Q3
3 quarters
IQV icon
60
IQVIA
IQV
$43.8B
$1.31M 0.09%
6,024
-53,546
-90% -$11.6M
2020 Q4
6 quarters
LH icon
61
Labcorp
LH
$26B
$1.25M 0.09%
6,232
-37,895
-86% -$8.08M
2021 Q3
3 quarters
WHWK icon
62
Whitehawk Therapeutics
WHWK
$169M
$1.24M 0.09%
100,817
-50,000
-33% -$743K
2022 Q1
1 quarter
ICLR icon
63
Icon
ICLR
$13.2B
$1.21M 0.09%
5,587
-41,229
-88% -$9.25M
2021 Q3
3 quarters
DXCM icon
64
DexCom
DXCM
$32.5B
$1.08M 0.08%
14,468
-99,148
-87% -$9.05M
2020 Q4
6 quarters
ZNTL icon
65
Zentalis Pharmaceuticals
ZNTL
$204M
$1.08M 0.08%
38,342
-61,845
-62% -$1.64M
2021 Q4
2 quarters
RGEN icon
66
Repligen
RGEN
$11.1B
$925K 0.07%
5,693
-30,828
-84% -$4.88M
2021 Q1
5 quarters
MIST icon
67
Milestone Pharmaceuticals
MIST
$91.7M
$905K 0.06%
147,165
– –
2021 Q3
3 quarters
MASI icon
68
DELISTED
Masimo
MASI
$782K 0.06%
5,984
-202,986
-97% -$27.2M
2022 Q1
1 quarter
CYH icon
69
CALL
Community Health Systems
CYH
$409M
$750K 0.05%
+200,000
New +$1.41M
2022 Q2
0 quarters
HSKA
70
DELISTED
Heska Corp
HSKA
$735K 0.05%
7,772
+1,936
+33% +$209K
2019 Q1
13 quarters
TEVA icon
71
CALL
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$699K 0.05%
92,900
– –
2021 Q2
4 quarters
SWAV icon
72
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$631K 0.04%
+3,300
New +$583K
2022 Q2
0 quarters
ACIU icon
73
AC Immune
ACIU
$240M
$450K 0.03%
124,589
– –
2021 Q3
3 quarters
SNDA icon
74
Sonida Senior Living
SNDA
$1.69B
$319K 0.02%
15,209
– –
2021 Q4
2 quarters
ELDN icon
75
Eledon Pharmaceuticals
ELDN
$176M
$144K 0.01%
59,065
-54,943
-48% -$168K
2021 Q3
3 quarters
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.